RVXCF (Resverlogix) Cash-to-Debt : 0.01 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Resverlogix's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Resverlogix couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Resverlogix's Cash-to-Debt or its related term are showing as below:

RVXCF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.59
Current: 0.01

During the past 13 years, Resverlogix's highest Cash to Debt Ratio was 0.59. The lowest was 0.00. And the median was 0.03.

RVXCF's Cash-to-Debt is ranked worse than
98.85% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs RVXCF: 0.01

Resverlogix Cash-to-Debt Historical Data

The historical data trend for Resverlogix's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Resverlogix Cash-to-Debt Chart

Resverlogix Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

0.01

Resverlogix Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															-	0.01	0.01	0.01	0.01

Competitive Comparison of Resverlogix's Cash-to-Debt

For the Biotechnology subindustry, Resverlogix's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resverlogix's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Resverlogix Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Resverlogix's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.099	/	(8.339	+	8.131)
	=	0.01

Resverlogix's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.099	/	(8.339	+	8.131)
	=	0.01

Resverlogix (OTCPK:RVXCF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Resverlogix Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Resverlogix's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.